The Future of Weight Loss Science

What's Next?

The science is moving fast. A new generation of medications is in clinical trials — including the first triple-action drug that targets three receptors at once. Here's what's coming and why it matters.

The evolution: from single to triple

Weight loss medications have evolved rapidly. First-generation drugs targeted one receptor (GLP-1). Tirzepatide added a second (GIP). Now, retatrutide targets three — adding glucagon, which actively increases calorie burning on top of appetite reduction.

Generation	Examples	Targets	Avg Weight Loss
Current single (GLP-1)	Ozempic, Wegovy, Saxenda	1 receptor	~15-17%
Current dual (GIP + GLP-1)	Mounjaro, Zepbound	2 receptors	~20-22%
Next-gen triple	Retatrutide	3 receptors	~24% (trials)
Next-gen combinations	CagriSema, Survodutide	2 pathways	~15-19% (trials)
Oral option	Orforglipron	1 receptor (pill)	~15% (trials)

Medications in the pipeline

Retatrutide

Phase 3 clinical trials

Eli Lilly · Triple agonist (GIP + GLP-1 + Glucagon)

Potential approval: 2026-2027

How it works

The first triple-action medication targeting three receptors simultaneously. The added glucagon receptor activation increases energy expenditure (calorie burning) on top of the appetite suppression from GLP-1 and GIP.

Trial results so far

In the Phase 2 trial, participants on the highest dose (12mg) lost an average of 24.2% of body weight over 48 weeks. Lower doses (8mg) showed ~22.8% loss.

Why it matters

✓Phase 2 trials showed up to 24% body weight loss at the highest dose — more than any current medication
✓The glucagon component may help burn fat more directly, not just reduce appetite
✓Could be particularly effective for people who plateaued on dual agonists like tirzepatide
✓May also benefit liver health — early data shows significant reduction in liver fat

Things to consider

⚠Still in trials — not yet approved or available to prescribe
⚠Side effect profile is similar to existing GLP-1s (nausea, GI issues) but may differ at higher doses
⚠Pricing and availability are unknown until approval
⚠The glucagon component raises theoretical concerns about blood sugar in some patients

Orforglipron

Phase 3 clinical trials

Eli Lilly · Oral GLP-1 receptor agonist

Potential approval: 2026

How it works

A GLP-1 receptor agonist that comes as a daily pill instead of an injection. Uses a different molecular structure (non-peptide) that survives stomach acid, unlike oral semaglutide which requires special formulation.

Trial results so far

Phase 2 data showed 14.7% body weight loss at the highest dose (45mg) over 36 weeks, with Phase 3 results expected to provide longer-term data.

Why it matters

✓No injections — a daily pill could dramatically increase the number of people willing to try GLP-1 treatment
✓Phase 2 trials showed up to 14.7% body weight loss over 36 weeks
✓Potentially much cheaper to manufacture than injectable biologics
✓Could make GLP-1 treatment accessible to people who are needle-averse or can't self-inject

Things to consider

⚠Weight loss results so far are lower than injectable options, though trials are ongoing
⚠Daily dosing vs weekly injection — some may prefer the convenience of weekly
⚠Still in trials — efficacy and safety data are preliminary
⚠Oral medications can have different absorption and side effect profiles

CagriSema

Phase 3 clinical trials

Novo Nordisk · Combination: Semaglutide + Cagrilintide (amylin analogue)

Potential approval: 2026-2027

How it works

Combines semaglutide (the active ingredient in Ozempic/Wegovy) with cagrilintide, which mimics the amylin hormone. Amylin is released alongside insulin after meals and helps regulate appetite through a different brain pathway than GLP-1.

Trial results so far

Phase 2 results showed 15.6% body weight loss over 32 weeks at the highest dose combination, outperforming semaglutide alone (5.1%) over the same period.

Why it matters

✓Attacks appetite through two different hormonal pathways simultaneously
✓Phase 2 trials showed up to 15.6% weight loss at 32 weeks — and weight was still declining at study end
✓Built on semaglutide which has extensive real-world safety data
✓The dual-pathway approach may help people who've stopped responding to GLP-1 alone

Things to consider

⚠Still a weekly injection (single combined pen)
⚠Novo Nordisk has had supply issues with Wegovy — similar risks possible
⚠Cost will likely be premium as a combination therapy
⚠Amylin analogues can cause nausea independently, so side effects may compound

Survodutide

Phase 3 clinical trials

Boehringer Ingelheim / Zealand Pharma · Dual agonist (GLP-1 + Glucagon)

Potential approval: 2027+

How it works

A dual agonist targeting GLP-1 and glucagon receptors (different combination to tirzepatide which targets GIP + GLP-1). The glucagon component aims to increase energy expenditure and improve liver fat metabolism.

Trial results so far

Phase 2 trial showed 19% body weight loss over 46 weeks, with significant reductions in liver fat content in patients with fatty liver disease.

Why it matters

✓Phase 2 trials showed up to 19% weight loss at 46 weeks
✓Particularly promising for fatty liver disease (MASH/NASH) — a condition affecting many people with obesity
✓The glucagon + GLP-1 combination may offer a different profile to GIP + GLP-1 drugs
✓Could become the treatment of choice for patients with both obesity and liver disease

Things to consider

⚠Weekly injection
⚠The glucagon component could theoretically affect blood sugar regulation
⚠Less clinical data than semaglutide or tirzepatide at this stage
⚠Positioning will likely focus on liver disease as well as weight management

What does this mean for you?

If you're currently on a GLP-1

• Don't switch or stop your current medication based on pipeline news
• The habits you're building now (protein, strength training) will matter regardless of which medication you take
• Discuss newer options with your doctor when they become available
• More competition should eventually mean lower prices

If you're considering treatment

• Don't wait for the “perfect” medication — current options are already highly effective
• Starting your lifestyle changes now means you'll be ahead when better options arrive
• An oral option (orforglipron) may be available soon if injections are a barrier for you
• The science is only getting better — this field is moving fast

View current medications →

Important note

The medications listed on this page are in clinical trials and are not yet approved or available to prescribe. Trial results are preliminary and may change. Approval timelines are estimates only. This information is for educational purposes — do not make treatment decisions based on pipeline medications. Always consult your doctor about currently available options.